NTRA - ナテラ （Natera Inc.） ナテラNTRAのチャート
NTRAの企業情報
| symbol | NTRA |
|---|---|
| 会社名 | Natera Inc （ナテラ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical Specialities |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 ナテラ(Natera Inc.)は診断会社である。同社は遺伝子検査サービスの発見・開発・商品化に従事する。同社は、母親から採血した胎児の染色体異常をスクリーニングするパノラマ非侵襲性出生前検査、キャリアの子供に渡される可能性のある多数の重度の遺伝病のキャリアステータスを決定するホライゾンキャリアスクリーニング、体外受精サイクル中に染色体異常または遺伝的遺伝的状態を分析して健康な子供になる可能性のある胚を選択するスペクトラムプレ移植遺伝子スクリーニングとスペクトラムプレ移植遺伝子診断、流産の原因を理解するために胎児の染色体を分析する受胎テストのAnora製品、並びに妊娠している母親の血液中の胎児性デオキシリボ核酸の断片と、疑わしい父親由来の血液サンプルを分析することにより父性を決定する非侵襲性父性検査を提供する。 ナテラは米国の遺伝子検査サ―ビス会社。主に出生前の遺伝子検査を提供する。体外受精において、着床前遺伝子スクリ―ニングを提供し、染色体異常や遺伝性遺伝子の状態を解析することで、受精胚の選択を可能にする。また、胎児の染色体異常を発見する検査や実父確定検査なども提供する。本社はカリフォルニア州サンカルロス。 Naterais a pioneer and global leader in cell-free DNA testing from a simple blood draw. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology, and organ health. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas. It offers proprietary genetic testing services to inform obstetricians, transplant physicians, oncologists, and cancer researchers, including biopharmaceutical companies, and genetic laboratories through its cloud-based software platform. |
| 本社所在地 | 201 Industrial Road Suite 410 San Carlos CA 94070 USA |
| 代表者氏名 | Matthew Rabinowitz マシュー・ラビノウィッツ |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer Co-Founder |
| 電話番号 | +1 650-249-9090 |
| 設立年月日 | 37926 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 893人 |
| url | www.natera.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ntra |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -120.49200 |
| 終値（lastsale） | 21.31 |
| 時価総額（marketcap） | 1298720475.8 |
| 時価総額 | 時価総額（百万ドル） 1225.587 |
| 売上高 | 売上高（百万ドル） 235.83000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1265.723 |
| 当期純利益 | 当期純利益（百万ドル） -139.31800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Natera Inc revenues increased 23% to $125.4M. Net loss increased 7% to $66.7M. Revenues reflect United States segment increase of 21% to $107M Europe Middle East India Africa segment increase of 91% to $13.1M. Higher net loss reflects Interest and other income decrease from $887K (income) to $3.8M (expense) Interest expense increase from $401K to $4.9M (expense). |
NTRAのテクニカル分析
NTRAのニュース
Natera and Genentech Initiate Phase III Trial Using Signatera™ as a Companion Diagnostic for Atezolizumab in Early-Stage Muscle-Invasive Bladder Cancer 2021/03/10 14:03:00 PR Newswire
AUSTIN, Texas, March 10, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that the first patient has been screened in a new phase III clinical trial that uses its tumor-informed, personalized molecular residual disease…
Preimplantation Genetic Diagnosis Market - Abbott Laboratories, Illumina, Inc., Natera Inc., PerkinElmer, Inc., F. Hoffman-La-Roche Ltd, Thermo Fisher Scientific, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics, Inc., Reproductive Gene 2021/03/08 06:32:40 OpenPR
Preimplantation Genetic Diagnosis Market Report 2020-2027 includes a comprehensive analysis of the present Market. The report starts with the basic Preimplantation Genetic Diagnosis industry overview and then goes into each and every detail. Preimplantation Genetic Diagnosis Market Report contains in depth
Natera Reports Fourth Quarter and Year 2020 Financial Results 2021/02/25 21:05:00 PR Newswire
SAN CARLOS, Calif., Feb. 25, 2021 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided an update on recent business progress. Recent…
Natera Announces Fourth Quarter and Fiscal 2020 Earnings Conference Call 2021/02/18 14:03:00 PR Newswire
SAN CARLOS, Calif., Feb. 18, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2020, after the market close on February 25, 2021. Natera…
Natera and Personalis Partner for Personalized Monitoring in Oncology 2021/02/17 14:01:00 Business Wire
MENLO PARK, Calif. & SAN CARLOS, Calif.--(BUSINESS WIRE)---- $NTRA #PrecisionOncology--Natera and Personalis Partner for Personalized Monitoring in Oncology
Natera Reports Fourth Quarter and Year 2020 Financial Results 2021/02/25 21:05:00 PR Newswire
SAN CARLOS, Calif., Feb. 25, 2021 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided an update on recent business progress. Recent…
Natera Announces Fourth Quarter and Fiscal 2020 Earnings Conference Call 2021/02/18 14:03:00 PR Newswire
SAN CARLOS, Calif., Feb. 18, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that it will release results for its fourth quarter and year ended December 31, 2020, after the market close on February 25, 2021. Natera…
Natera and Personalis Partner for Personalized Monitoring in Oncology 2021/02/17 14:01:00 Business Wire
MENLO PARK, Calif. & SAN CARLOS, Calif.--(BUSINESS WIRE)---- $NTRA #PrecisionOncology--Natera and Personalis Partner for Personalized Monitoring in Oncology
Natera to Participate in Upcoming Investor Conferences 2021/02/11 14:03:00 PR Newswire
SAN CARLOS, Calif., Feb. 11, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced that Alexey Aleshin, MD, Natera's Senior Medical Director of Oncology, will participate in a panel discussion at the BTIG Virtual MedTech,…
Global Non-Invasive Prenatal Testing (NIPT) Market By Top Players: Sequenom, Roche (Ariosa Diagnostics); Natera, LabCorp, BGI Genomics; Quest Diagnostics, Illumina, Laboratory Corporation of America Holdings, Yourgene Health, and Berry Genomics. 2021/02/04 11:52:11 OpenPR
The report "Global Non-Invasive Prenatal Testing (NIPT) Market, By Product Type (Devices, Consumables, and Others), By Techniques (cfDNA, Biochemical Screening Tests, and Ultrasound Detection), By Application (Trisomy, Microdeletion syndrome, and Others), By End-User (Diagnostic Laboratories, Hospitals, and Cell DNA screening),
Global Non-Invasive Prenatal Testing (NIPT) Market By Top Players: Sequenom, Roche (Ariosa Diagnostics); Natera, LabCorp, BGI Genomics; Quest Diagnostics, Illumina, Laboratory Corporation of America Holdings, Yourgene Health, and Berry Genomics. 2021/02/04 11:52:11 OpenPR
The report "Global Non-Invasive Prenatal Testing (NIPT) Market, By Product Type (Devices, Consumables, and Others), By Techniques (cfDNA, Biochemical Screening Tests, and Ultrasound Detection), By Application (Trisomy, Microdeletion syndrome, and Others), By End-User (Diagnostic Laboratories, Hospitals, and Cell DNA screening),
Panorama® SMART Study Confirms Market-Leading Performance in Largest Prospective NIPT Trial to Date 2021/02/03 14:03:00 PR Newswire
SAN CARLOS, Calif., Feb. 3, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cfDNA testing, presented key results from its SMART study at the SMFM 41st Annual Pregnancy Meeting.1-3 The SMART study is the largest prospective, multi-site study ever performed…
SMART Study Finds 22q11.2 Microdeletion Prevalence Much Higher than Expected 2021/02/01 14:03:00 PR Newswire
SAN CARLOS, Calif., Feb. 1, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cfDNA testing, presented key results from its SMART study at the SMFM 41st Annual Pregnancy Meeting.1 The SMART study sets a new standard as the largest prospective NIPT study to…